Scribd Logo
Upload

Welcome to Scribd!

  • 131 views

    Glenmark Report

    Uploaded by

    BKS
    Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days. Glenmark will market the antiviral under the brand name ‘FabiFlu®’.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Glenmark Report

    Uploaded by

    BKS
    131 views3 pages
    Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days. Glenmark will market the antiviral under the brand name ‘FabiFlu®’.

    Original Title

    Glenmark report

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days. Glenmark will market the antiviral under the brand name ‘FabiFlu®’.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    131 views3 pages

    Glenmark Report

    Uploaded by

    BKS
    Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19. Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days. Glenmark will market the antiviral under the brand name ‘FabiFlu®’.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 3

    June 20, 2020

    To, To,
    Dy. General Manager The Manager – Listing,
    Department of Corporate Services, The National Stock Exchange of India Ltd.,
    BSE Ltd., Plot No. C/1, G Block,
    P. J. Towers, Dalal Street, Bandra Kurla Complex,
    Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051.

    Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

    Dear Sir,

    Sub: Glenmark becomes the first pharmaceutical company in India to receive regulatory
    approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

    With reference to the subject mentioned above, kindly find attached media release which is self-
    explanatory.

    Request you to kindly take the same on record.

    Thanking you,

    Yours faithfully,
    For Glenmark Pharmaceuticals Limited
    HARISH
    Digitally signed by HARISH VINAYAK KUBER
    DN: c=IN, st=Maharashtra,
    2.5.4.20=cde2956f5be913821f9f9f91026d376afdaebf5fb8838c3a71d
    e2e75255a782d, postalCode=400049, street=C21, Maker Kundan

    VINAYAK KUBER
    Garden,
    serialNumber=afdac79f9832ea525179ba4771e8bfb76ef0e3cac49116
    0cbf271c80d4b16e4f, o=Personal, cn=HARISH VINAYAK KUBER
    Date: 2020.06.20 11:55:20 +05'30'

    Harish Kuber
    Company Secretary & Compliance Officer

    Encl: as above

    Glenmark Pharmaceuticals Ltd.


    Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
    T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
    Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [email protected]
    Press release For immediate distribution

    Glenmark becomes the first pharmaceutical company in India to receive


    regulatory approval for oral antiviral Favipiravir, for the treatment of mild
    to moderate COVID-19

     Manufacturing and marketing approval granted as part of accelerated approval process, considering the
    emergency situation of the COVID-19 outbreak in India
     The approval’s restricted use entails responsible medication use where every patient must have signed
    informed consent before treatment initiation
     Favipiravir shows clinical improvements of up to 88% in COVID-19, with rapid reduction in viral load by 4 days
     Clinical improvement noted across age groups 20 to >90 years, including in patients with co-morbid
    conditions like diabetes and heart disease suffering from mild to moderate COVID-19
     Glenmark to market the antiviral under the brand name ‘FabiFlu®’

    Mumbai, India; June 20, 2020: In a landmark development for COVID-19 patients in India, Glenmark
    Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced the launch of
    antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients.
    Glenmark has received manufacturing and marketing approval from India’s drug regulator, making
    FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of COVID-19.

    Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to
    moderate COVID-19. The antiviral offers broad spectrum RNA virus coverage2 with clinical improvement
    noted across age groups 20 to >90 years.3 Favipiravir can be used in COVID-19 patients with co-morbid
    conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms.3 It offers rapid
    reduction in viral load within 4 days1,4 and provides faster symptomatic and radiological improvement.1,4,5
    Of most importance, Favipiravir has shown clinical improvement of up to 88% in COVID-19 mild to
    moderate COVID 19 cases.3

    Glenmark successfully developed the active pharmaceutical ingredient (API) and the formulation for
    FabiFlu® through its own in-house R&D team. Glenmark filed the product for clinical trial with India’s
    drug regulator DCGI and became the first pharmaceutical company in India to receive approval for
    conducting phase 3 clinical trial on mild to moderate COVID-19 patients.

    Commenting on the significance of this development, Mr. Glenn Saldanha, Chairman and Managing
    Director of Glenmark Pharmaceuticals Ltd., said, “This approval comes at a time when cases in India are
    spiralling like never before, putting a tremendous pressure on our healthcare system. We hope the
    availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure, and
    offer patients in India a much needed and timely therapy option.”
    He added, “FabiFlu® has demonstrated an encouraging response in mild to moderate COVID-19 patients
    during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment
    option over other intravenously administered medications. Glenmark will work closely with the
    government and medical community to make FabiFlu® quickly accessible to patients across the country.”

    Favipiravir is approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus
    infections. It has a unique mechanism of action: it is converted into an active phosphoribosylated form
    (favipiravir-RTP) in cells and recognized as a substrate by viral RNA polymerase, thereby inhibiting RNA
    polymerase activity.

    Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu® use. The drug will be
    available as a prescription-based medication for INR 103/tablet, with recommended dose being 1800 mg
    twice daily on day 1, followed by 800 mg twice daily up to day 14.

    Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the
    efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized
    adult COVID-19 patients in India.

    —End—

    About Glenmark Pharmaceuticals Ltd


    Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence
    across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy
    focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma &
    Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For
    more information, visit www.glenmarkpharma.com

    For more information:


    Glenmark Media Contacts
    Madhurima Gupta Jain Udaykumar Murthy
    Senior Manager, Corporate Communications Senior Manager, Corporate Communications
    +91 9819382087 +91 9960377617
    [email protected]

    References:
    1. https://rdif.ru/Eng_fullNews/5224/

    2. Furtuta Y et al. Antiviral Res. 2013;100(2):446-54.

    3. http://www.kansensho.or.jp/uploads/files/topics/ 2019ncov/covid19_casereport_en_200529.pdf

    4. Cai Q et al. Engineering (Beijing), 2020;10.1016/j.eng.2020.03.007

    5. Chen C et al. MedRxiv. 2020 Jan 1

    You might also like